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Abstract
Background: Insertional mutagenesis screens in the mouse are an acknowledged approach to identify genes involved 
in the pathogenesis of cancer. The potential of these screens to identify genes causally involved in tumorigenesis is not 
only limited to the murine host, but many of these genes have also been proven to be involved in the oncogenic 
process in man.
Results: Through an insertional mutagenesis screen applying murine leukemia viruses in mouse, we found that Cd74 
was targeted by proviral insertion in tumors of B-cell origin. This locus encodes a protein playing crucial roles in antigen 
presentation and B-cell homeostasis, and its deregulation is often associated with cancer in man. The distribution of 
insertions within the Cd74 locus prompted the identification of an alternative transcript initiated in intron 1 of Cd74 
encoding an N-terminally truncated Cd74 isoform in tissues from un-infected mice, and transcriptional activation 
assays revealed a positive effect on the novel intronic promoter by a formerly described intronic enhancer in the Cd74 
locus. Furthermore, we show that the new Cd74 isoform is IFNγ inducible and that its expression is differentially 
regulated from the canonical Cd74 isoform at the transcriptional level.
Conclusions: We here identify Cd74 as a common insertion site in murine B-lymphomas and describe a novel IFNγ-
inducible murine Cd74 isoform differentially regulated from the canonical isoform and expressed under the control of 
an intronic promoter. The distribution and orientation of proviral insertion sites within the Cd74 locus underscores the 
causal involvement of the isoforms in the murine B-lymphomagenic process.
Background
Cd74 (CD74 in man) is a non-polymorphic type II mem-
brane-spanning glycoprotein, which was originally identi-
fied as being associated with antigen presentation by
dimeric major histocompatibility complex class II
(MHCII) molecules. The roles played by Cd74 in antigen
presentation span from chaperoning MHCII dimers in
their proper folding, preventing premature antigenic pep-
tide loading in the ER, and promoting ER egress of
MHCII dimers, to targeting these complexes to endocytic
compartments [1-3]. However, Cd74 is also required for
follicular B-cell maturation as well as maintenance of the
follicular and marginal zone B-cell pools [4,5], and this
action is independent of the MHCII-chaperonic activity
of Cd74 [6]. The vast majority of MHCII-Cd74 complexes
are diverted to the endocytic system, but surface expres-
sion of a small proportion of cellular Cd74 can indeed be
detected on B-cells independently of concomitant class II
expression [7-9]. These Cd74 cell surface molecules
reveal high affinity binding to the pro-inflammatory
cytokine macrophage migration inhibitory factor (MIF),
and together with the signaling component of the MIF-
Cd74 receptor complex (CD44) transmit MIF-mediated
signaling [10,11]. Activation of cell surface Cd74 by MIF
induces a signaling cascade leading to Cd74 intra-mem-
brane cleavage, release of the N-terminal cytoplasmic
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part of Cd74, NF-κB activation, and ultimately, increased
expression of the anti-apoptotic factor Bcl-2 [12-15]. This
signaling cascade defines Cd74 as a survival receptor
enhancing the survival of mature B-cells. Furthermore,
Cd74 was also shown to act as a regulator of dendritic
and B-cell motility [16].
In normal tissues, Cd74 is expressed on B cells, mono-
cytes, macrophages, dendritic cells and epithelial cells of
endodermal and mesodermal origin [17]. The transcrip-
tional control elements for the murine Cd74 locus are
composed of a promoter with common regulatory ele-
ments such as TATA-box, Sp1 site, CCAAT-box, and an
NF-κB responsive element as well as an upstream
enhancer with elements corresponding to promoter ele-
ments in MHCII [18]. Additionally, two distinct intronic
enhancers are found in intron 1 [19,20]. In mouse differ-
ential splicing gives rise to two different isoforms, p31
and p41, with the p41 isoform harboring an additional
exon (exon6b) as compared to p31 [21] whereas in man
differential splicing combined with alternative transla-
tional start sites gives rise to four distinct CD74 isoforms
[22,23]. The mRNA transcripts for human p41 and p43,
the longer isoform translated from an upstream ATG,
comprise 10% of the total CD74 transcript pool [22].
Cd74 is involved in many different scenarios, however
analysis of Cd74 function in transgenic mice expressing
exclusively one of the two isoforms indicates that in most
respects the two isoforms can be regarded as functionally
redundant [24-26].
Given its diverse functions in B-cell homeostasis it is
not surprising that human CD74 is strongly expressed in
a variety of B-cell lymphomas as well as many cell lines
derived thereof [27-29]. B-cell chronic lymphocytic leu-
kemia (B-CLL) is characterized by a progressive accumu-
lation of B-lymphocytes in peripheral blood, lymphoid
organs, and bone marrow, due to decreased apoptosis of
this cell population. Evaluation of CD74 function in B-
cells purified from the peripheral blood of B-CLL patients
revealed that cell surface stimulation of CD74 initiated a
signaling cascade leading to promotion of cell survival
[30]. Many studies have furthermore demonstrated CD74
expression in various non-hematological cancers includ-
ing gastric, colon, lung, and renal epithelial cancers [31-
34], and moreover has the elevated expression level in
several cancers served as a marker for tumor progression
and/or poor clinical outcome [35]. The selective expres-
sion pattern of CD74 in neoplastic processes combined
with the dynamics of internalization of cell surface CD74
molecules have brought CD74 forward as an attractive
target for monoclonal antibody-based therapy [35]. In
that connection, preclinical studies revealed that a
humanized form of a murine Cd74 antibody is able to
effectively inhibit tumor growth and yielded marked sur-
vival improvements in severe combined immunodefi-
ciency mouse xenograft models of non-Hodgkin
lymphomas and multiple myeloma, respectively [36].
Currently, phase I and phase I/II trials are underway in
patients with B-cell non-Hodgkin lymphomas and B-
CLL, and one including patients with multiple myeloma
has been completed [37].
Proviral tagging is a widely applied and efficient tool in
the discovery of oncogenes relying on the mechanism of
retroviral insertional mutagenesis [38,39]. In an attempt
to broaden the understanding of the causative genetic
alterations in hematopoietic tumors, we have used the
inbred NMRI mouse strain infected with the non-acutely
transforming ecotropic murine leukemia viruses (MLVs)
Akv and SL3-3, giving rise to models of B- and T-cell
tumorigenesis, respectively [40,41]. We here report of the
identification of Cd74 as a novel common insertion site in
retrovirally induced murine B-lymphomas, thereby pro-
viding a strong genetic indication for causal involvement
of this locus in B-lymphomagenesis. Prompted by the dis-
tribution and orientation of insertion sites within the
Cd74  locus a hitherto uncharacterized intronic Cd74
promoter was identified in tissues from un-infected mice
leading to expression of an N-terminally truncated Cd74
isoform. The distinct intronic promoter is positively reg-
ulated by the 3' Cd74 intronic enhancer and the expres-
sion of the novel Cd74 isoform is IFNγ responsive in
analogy with the canonical Cd74 isoform.
Results
Cd74 is a frequently targeted novel common insertion site
In a retroviral screen of app. 2400 tumors, 44 proviral
insertion sites were identified within the locus encoding
Cd74, with tumors harboring only a single integration in
Cd74 per tumor in all but two cases. All insertions were
found exclusively upstream of exon 5, displaying no gen-
eral orientation preference, within a small window of 8.7
kb (Figure 1).
The screen resulted in about 7800 retroviral tags and
assuming random distribution of these in the 3.2 gb
murine genome, this would result in app. one integration
per 410 kb in this screen, leading to an expected fre-
quency of ~ 0.02 of randomly tagging the Cd74 locus
which spans app. 9 kb. Therefore, identification of 44
integration sites within this small region is ~ 2200 times
higher than expected if the locus were hit merely by
chance. Furthermore, whereas the insertions in Cd74 co-
transcriptional orientation were dispersed over the entire
region upstream exon 5, all the proviral insertions in
opposite transcriptional orientation to Cd74  clustered
within intron 1 and upstream intron 2 (insertions in
tumor 01-931, 99-34, the downstream insertion in 99-
919, and 98-1130 were in exon 2, see Figure 1). This
clearly indicates a selective preference for integrated pro-
viruses of inverse transcriptional directionality to bePyrz et al. Molecular Cancer 2010, 9:86
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found within intron 1. Collectively, these observations of
high frequency and non-randomness in insertional posi-
tion and orientation serve as powerful genetic arguments
of positive selection for Cd74  insertions during lym-
phomagenesis.
The Retroviral Tagged Cancer Gene Database
(RTCGD) collects data from multiple high-through-put
retroviral insertional screens, enabling cross-screen
searches for common insertion sites (CIS) [42,43].
Although the database currently contains nearly 7000 ret-
roviral insertion sites Cd74 could not be found in RTCGD
as tagged by insertional integration.
Targeting of the Cd74 locus is specific for B-
lymphomagenic MLVs
The tumors included in this screen were induced by Akv,
SL3-3 and mutants hereof and the tumor bank consisted
of app. equal sample sizes of tumors induced by MLVs
possessing a B-lymphomagenic potential and T-lym-
phomagenic MLVs, respectively. As can be seen in table 1,
40 of the 42 tumors were induced by viruses of the Akv
type possessing a strictly B-lymphomagenic potential.
The remaining two tumors were induced by viruses with
the B-lymphomagenic potential being one among others
(SL3-3(AML1dm) [44] and Akv/SL3-3 TM (Unpub-
lished)). Thus, despite the composition of the tumor
bank, tumors with integration in Cd74 shared the com-
mon characteristic of being induced by B-lymphom-
agenic viruses.
Rearrangements within immunoglobulin (Ig) and T-cell
receptor (TCR) genes, normally occurring during B- and
T-cell development, are useful diagnostic markers for
determining the cell lineage of lymphomas. In accordance
with a common B-lymphomagenic potential of the
viruses applied for tumor induction of Cd74-targeted
tumors and the tumor target tissue, no general pattern of
rearrangements in the TCRβ chain was detected indicat-
ing that these tumors indeed were not in general of T-cell
type. In a single tumor concomitant IgH and TCRβ chain
rearrangements were detected, however, this pattern has
also been seen in human B-cell malignancies [45]. Sur-
prisingly, rearrangements in Ig loci could be identified in
Figure 1 Integration pattern in the Cd74 locus. Shaded boxes indicate coding sequences and open boxes non-coding regions, numbers represent 
tumor IDs, and arrowheads indicate proviral orientation in relation to transcriptional direction. Asterisks mark two tumors (99-919 and 01-898) each 
harboring two integrations.Pyrz et al. Molecular Cancer 2010, 9:86
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Table 1: Tumor panel with integrations in the Cd74 locus
Tumor ID 
and tissuea
Virus variantb Lymphomagenic 
potential of virus variant
Lymphoma 
incidence n/total
Mean latency in daysc Latency in daysd
01-340s Akv wt Be 36/39 185 ± 26 194
01-367s Akv wt Be 36/39 185 ± 26 190
01-617s Akv wt Be 36/39 185 ± 26 251
99-919m Akv1-99 wt Be 67/70 181 ± 26 150
99-1206c Akv1-99 wt Be 67/70 181 ± 26 209
01-454s Akv1-99 wt Be 67/70 181 ± 26 198
99-34m Akv PBS-Arg Bf 19/19 178 ± 17 172
99-162c Akv PBS-Gln Bf 23/23 182 ± 27 204
99-18m Akv PBS-Lys Bg 19/20 206 ± 30 172
99-115c Akv PBS-Lys Bg 19/20 206 ± 30 204
99-191t Akv PBS-Lys Bg 19/20 206 ± 30 225
98-1130s Akv PBS-Pro Bf 20/20 161 ± 36 131
01-1064s Akv1-99 (mAML1+mEgre) Bh 45/46 199 ± 35 232
01-671s Akv1-99 (mEts) Bh 43/44 182 ± 27 163
01-700s Akv1-99 (mEts) Bh 43/44 182 ± 27 169
01-762s Akv1-99 (mEts) Bh 43/44 182 ± 27 177
01-931s Akv1-99 (mEts) Bh 43/44 182 ± 27 204
99-1159s Akv1-99NF1m1 Bi 16/17 187 ± 19 199
01-656s Akv1-99NF1m2 Bi 44/44 182 ± 28 156
01-696s Akv1-99NF1m2 Bi 44/44 182 ± 28 162
01-785c Akv1-99NF1m2 Bi 44/44 182 ± 28 177
01-815c Akv1-99NF1m2 Bi 44/44 182 ± 28 181
01-843s Akv1-99NF1m2 Bi 44/44 182 ± 28 184
01-1067s Akv1-99NF1m2 Bi 44/44 182 ± 28 218
01-1069s Akv1-99mEa/s Bh 47/47 165 ± 23 183
01-844s Akv1-99mEa/s Bh 47/47 165 ± 23 149
01-898s Akv1-99mEa/s Bh 47/47 165 ± 23 158
99-306t SL3-3(AML1dm) Mixed, incl. B j 36/42 NA 175
01-552s Akv1-99 (mAML1) Bh 43/45 126 ± 40 162
01-720s Akv1-99 (mEgre) Bh 50/50 148 ± 47 185
03-462s Akv1-99 (mEgre) Bh 41/42 160 ± 27 154
01-773s Akv1-99 (mAML1+mGR) Bh 53/53 190 ± 31 203
01-1062m Akv1-99 (mAML1+mGR) Bh 53/53 190 ± 31 245
03-741s Akv1-99 (mEgre+mEa/s) Bh 41/41 183 ± 38 199
01-930s Akv1-99 (mEts) Bh 43/44 182 ± 27 204
03-793s Akv1-99 (mGr) Bh 40/41 145 ± 28 164
00-140n Akv SA' gag mutant (EH) Bk 17/18 184 ± 34 205
00-111n Akv SA' gag mutant (CD) Bk 17/19 201 ± 30 188
02-1156m Akv/SL3-3TM Ongoing work 23/23 139 ± 23 115
03-1160s Akv1-99 (mGR+mEa/s) Bh 46/49 186 ± 26 240Pyrz et al. Molecular Cancer 2010, 9:86
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only five of the 31 analyzed tumors (Figure 2A-C), indi-
cating that the tumors are sub-clonal with respect to
tumor cell of origin at the molecular level and/or contain
significant numbers of non-malignant cells.
Selected tumors with integration in Cd74 have been
examined by histopathology in connection to our earlier
work. As listed in table 2, 26 of the 42 tumors with provi-
ral insertion into the Cd74 locus were histopathologically
classified and in all 26 cases the hematopoietic neoplasm
was characterized to be of B-cell origin.
Non-uniformity in Cd74 expression among tumors
The Cd74 mRNA levels in tumor tissue harboring inte-
gration in the Cd74 locus were assessed by Northern blot
hybridizations in order to analyze possible effects of the
integrated proviruses on Cd74 expression pattern in the
MLV-induced B-lymphomas. As Cd74 is a key compo-
nent in the process of B-cell development, mRNA from
tumors from the same experimental series - but without
integration in the Cd74 locus - were included as controls,
in order to eliminate changes in Cd74 expression levels
due to common aspects of MLV infection and/or lym-
phomagenesis. Sixteen tumors with integration in Cd74
were subjected to Northern blot analysis, however, no
general pattern of over-expression or down-regulation
was evident when compared to controls (data not shown).
This observation was also reflected by Western blot anal-
yses of 24 of the 42 tumors when compared to Cd74
expression levels in control tumors (data not shown). The
lack of a general mode of transcriptional deregulation
could mirror the absence of clonal integrations within the
Cd74 locus in the tumors and/or be a consequence of a
high level of non-malignant infiltrating cells. To assess
whether clonal integrations could be identified in the
analyzed tumors, Southern blotting was performed with
an ecotropic envelope-specific probe. This revealed an
absence of clonal integrations on the global scale irre-
spective of target locus (Figure 2D), and was confirmed
for insertions in the locus of interest by Southern blotting
with Cd74-specific probes (data not shown). The appar-
ent sub-clonal nature of Akv-induced B-lymphomas in
i n b r e d  N M R I  m i c e  h a s  p r e v i o u s l y  b e e n  d e m o n s t r a t e d
and seems to be an inherent feature of these tumor mod-
els [46], nevertheless, the existence of CIS in these tumors
underscores the effects of insertional mutagenesis
[47,48].
In summary, the molecular analyses of end-stage tumor
tissues with integrations in Cd74 suggest a more complex
scenario of Cd74 function in B-cell tumors than onco-
genic over-expression or lack of tumor suppressor func-
tion.
Identification of a novel transcript initiated in intron 1 in 
the Cd74 locus
Deregulation of cellular genes by proviral insertion can be
achieved in different ways. Among other scenarios, provi-
ral elements regulating retroviral transcription are often
seen to influence cellular promoters when the provirus is
integrated upstream of genes in the antisense orientation.
Intron 1 is by far the largest intron in Cd74 with its 3897
bp. However, almost all of the antisense integrations in
intron 1 (16 out of 18) were found within a window of 950
bp in the 5' end of intron 1 (Figure 3A), suggesting the
possible existence of a novel intronic promoter between
the proviral integration cluster and exon 2. A forward
primer situated in intron 1 just upstream exon 2 and an
exon 4 reverse primer was applied in RT-PCRs and in all
tumors examined a transcript was identified (data not
shown), indicative of the existence of a novel promoter in
intron 1. We speculated that if a novel promoter were
activated in the tumors, we might also detect this tran-
script in tissues from un-infected mice and RT-PCR anal-
ysis did indeed reveal expression of a transcript
containing sequences from the 3' end of intron 1 in spleen
from un-infected NMRI mice (Figure 3B). The transcripts
initiated in intron 1 consisted of intron 1 sequences
extending into exon 2 and with a subsequent canonical
splicing pattern downstream of exon 2. The intronically
initiated transcript detected in tumor tissues was charac-
terized until exon 5 in which part it was identical in
sequence to the novel transcript identified in un-infected
tissues.
Furthermore, the amount of intronically initiated tran-
scripts harboring both exon 6 and exon 6b (i.e. being p41-
like) in tissues from un-infected mice was much lower
than the abundance of transcripts harboring only exon 6
(i.e. being p31 like) (data not shown), reflecting the rela-
00-216m Akv SA' gag mutant (EH) Bk 17/18 184 ± 34 232
99-1276s Akv SA' gag mutant (CDH) Bk 14/16 190 ± 46 163
aS indicates spleen; m, mesenteric lymph node; c, cervical lymph nodes; t, thymus; and n, lymph node of unspecified position. bIndicate the MLV 
injected into inbred NMRI mice for tumor induction. cIndicates the mean latency for tumor induction in mice infected with the same MLV as the 
one giving rise to the listed tumor with integration in Cd74. dIndicates the age of the mouse harboring the listed tumor at the point of cervical 
dislocation and tumor isolation. The pathogenic potential of these viruses were determined in the following studies; e[41], f(Unpublished), g[48], 
h[46], i[68], j[44], and k[67].
Table 1: Tumor panel with integrations in the Cd74 locus (Continued)Pyrz et al. Molecular Cancer 2010, 9:86
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tive transcript abundance seen in the human CD74 tran-
script pool [22].
RT-PCRs with a Cd74-specific exon 1 forward primer
and several intron 1 reverse primers, of which one was
positioned immediately upstream exon 2 did not yield
any amplification products indicating that the novel tran-
script is not an aberrantly spliced isoform of the canoni-
cal transcript. In order to identify the transcriptional
initiation site of the novel transcript, RNA-ligase-medi-
ated rapid amplification of cDNA ends (RLM-RACE)
PCR was performed on RNA purified from two different
spleens and PCRs were run with a reverse primer in
intron 1 (SR2, Figure 3C). The amplification products
were cloned and sequenced and transcriptional initiation
sites were in both cases dispersed over a region of app.
100 bp (Figure 3C). In validation of the cDNA synthesis,
the canonical transcript was identified by RT-PCR with
appropriate primers (data not shown). Thus, in tissues of
un-infected mice a transcript is initiated within the 3'
part of intron 1 - most likely driven by a broad-peak pro-
moter.
Expression of the novel Cd74 isoform
Expression of CD74 in the human fetus has been detected
in most tissues by immunohistochemistry, where in many
cases scattered CD74 staining within non-hematopoietic
organs was localized to the interstitium of organ paren-
chyma [17]. In order to determine the expression pattern
of the novel alternative transcript, RT-PCR analysis was
performed on different tissues from BALB/c mice. The
highest expression of the alternative transcript was seen
in spleen, bone marrow, and thymus but the transcript
could also be detected in kidney, uterus, ovary, and pros-
tate. Expression of the alternative transcript could how-
e v e r  n o t  b e  d e t e c t e d  i n  c e r e b r u m ,  c e r e b e l l u m ,  t e s t i s ,
heart, liver, skeletal muscle, and lung (data not shown). In
contrast to that seen for the alternative transcript, expres-
sion of the canonical Cd74 transcript was identified in all
tissues analyzed. Accordingly, identification of the canon-
ical transcript in tissues not expressing the alternative
transcript indicates differential transcriptional regula-
tion of the two.
To establish the relative abundance of transcripts
derived from the canonical upstream promoter and the
novel intronic promoter, respectively, a qPCR-based assay
was conducted with standards based on absolute ampli-
con copy-number of the two different amplicons. This
revealed the alternative transcript to be a minor isoform
with the canonical transcript being 40-60 fold as abun-
dant in un-infected NMRI spleen (Figure 3D). Moreover,
in tumor 01-762, which harbors an integration in intron 1
in opposite transcriptional orientation to Cd74, the rela-
tive wildtype/alternative transcript ratio was slightly
shifted towards higher levels of alternative transcripts in
Figure 2 Southern blotting analysis. (A) and (B) Tumor DNA was an-
alyzed by Southern blot hybridization using probes detecting ger-
mline (g.l.) and rearranged configurations (arrowhead) of the Igκ locus 
(A), IgH locus (B) and the TCRβ chain (data not shown). DNA from 
spleen from un-injected NMRI mice was included as control (c) and tu-
mors with rearrangements are indicated in bold (lane 4 in (A): tumor ID 
99-115, lane 6 in (B): 01-340, and lane 8 in (B): 99-34). (C) List of all tu-
mors with detected rearrangements in any of the analyzed loci. (D) 
Evaluation of integration site clonality by Southern blotting analysis. 
Tumor DNA was analyzed by Southern blot hybridization using an eco-
tropic envelope-specific probe, the position of which is indicated. The 
blot exemplifies an analysis of DNA from seven tumors harboring inte-
gration in Cd74 (lanes marked by numbers), DNA from spleen of un-in-
fected NMRI mice (lane denoted C), and DNA from spleen of un-
infected BALB/c mice (lane denoted B). The lane denoted M contains 
the marker. BALB/c DNA contains one copy of an endogenous ecotro-
pic MLV (which upon NcoI digestion and hybridization with this probe 
yields a band of app. 7 kb), thus serving as a positive control for the en-
velope probe, whereas NMRI was included as a negative control as it 
does not harbor endogenous ecotropic MLVs. LTR denotes the long 
terminal repeats of integrated proviruses.Pyrz et al. Molecular Cancer 2010, 9:86
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accordance with transcriptional activation of the novel
isoform by the proviral insertion (Figure 3D, light grey
bar).
A novel Cd74 isoform encoded by the alternative transcript
The transcript generated by transcriptional initiation in
intron 1 was computationally scanned for open reading
frames (ORFs), and interestingly, an ORF was initiated 23
nucleotides upstream exon 2 and terminated in the 5' end
of exon 8 encoding a protein of 197 amino acids (aa).
Alignment of this novel ORF (of the p31-like exon com-
position) with that of the canonical p31 Cd74 isoform
(215 aa) revealed these to be identical from point of entry
into exon 2 sequences - thus, the canonical isoform har-
bors a 25 aa long unique N-terminal, whereas the first
seven aa's from the ORF of the alternative transcript are
unique to the novel isoform (Figure 4A). The ORF of the
alternative transcripts of the p41-type harboring the
additional exon did also align with the canonical p41 ORF
in an analogous manner. To verify the usage of the pre-
dicted start-codon in production of the novel isoform an
in vitro coupled transcription/translation assay was per-
formed and confirmed the translation to initiate at the
methionine 7 aa's upstream exon 2 (Figure 4B).
An intronic promoter in intron 1 of the Cd74 locus
Expression of an alternative Cd74 isoform driven by a
novel intronic promoter in normal tissues prompted the
search for cis-regulatory elements in the 3' end of intron
1. Initially, the entire Cd74  intron 1 sequence was
extracted and orthologous sequence chains from rat,
human, marmoset, horse, and cow, were obtained and
aligned by multiple alignment without gap-penalties with
the Chaos and Dialign software [49]. Within this genomic
region the largest degree of similarity, excluding the pre-
viously described intronic enhancer sequences [19,20],
was to be found in the 3' end of intron 1 downstream of
both intronic enhancers. This region coincided with the
putative location of the novel intronic promoter.
In order to identify possible conserved transcription
factor binding sites within this region in the murine Cd74
locus, and in orthologous sequences from rat, human,
marmoset, and horse, MatInspector software analysis
[50] was conducted with selection parameters ensuring
positioning only of predicted binding sites for transcrip-
tion factors expressed in the immune system with full or
nearly perfect match within the core sequence. Several
conserved ETS transcription factor binding sites were
identified, as well as putative binding sites for myeloid
zinc finger 1 (MZF1) (Figure 5A). In the murine sequence
two TATA-boxes were identified, however in both cases
these regulatory elements were predicted to be situated at
a distance to the transcriptional initiation region exceed-
ing that normally observed. In accordance with this, an
XCPE1 (X core promoter element 1) motif was identified
in the murine sequence, which has been correlated with
transcriptional activation of TATA-less promoters in
Table 2: Histopathological classification of tumors
Tumor ID and
tissue










01-367s DLBCL* 01-931s PCP‡ 99-34m ND
00-140n DLBCL* 01-1069s PCP‡ 99-162c ND
00-111n DLBCL* 01-844s PCP‡ 98-1130s ND
00-216m DLBCL* 01-898s PCP‡ 99-1159s ND
01-340s FBL* 03-462s PCP‡ 01-656s ND
99-18m FBL† 01-930s PCP‡ 99-306t ND
99-191t FBL† 01-696s PCP§ 01-552s ND
01-617s PCP* 01-785c PCP§ 01-720s ND
99-1276s PCP* 01-843s PCP§ 01-773s ND
01-454s PCP† 01-1067s PCP§ 01-1062m ND
01-1064s PCP‡ 01-815c PCP + SMZL§ 03-741s ND
01-671s PCP‡ 99-115c SMZL† 03-793s ND
01-700s PCP‡ 99-919m ND 02-1156m ND
01-762s PCP‡ 99-1206c ND 03-1160s ND
The histopathology of the tumors was evaluated in course of the following studies; *[67], †(Unpublished), ‡[46], and §[68]. DLBCL denotes 
diffuse large B-cell lymphoma; FBL, follicular B-cell lymphoma; PCP, plasma cell proliferations (consistent with plasmacytomas); SMZL, splenic 
marginal zone lymphoma; and ND, not determined. Denotation of tissue types as described in Table 1.Pyrz et al. Molecular Cancer 2010, 9:86
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higher eukaryotes [51]. Interestingly, an interferon (IFN)
regulatory factor binding site was predicted just down-
stream a conserved ETS1 site, which in mouse is com-
posed of two consecutive core sequences.
To assess the functional importance of the intronic
region harboring the conserved transcription factor bind-
ing sites, a plasmid based on the pGL3-enhancer
luciferase reporter was cloned in which the region har-
Figure 3 Identification of a transcriptional initiation region in Cd74 intron 1. (A) Overview of the number of integrations within the 3897 bp Cd74 
intron 1 illustrated in 100 bp windows. The window spanning the first 100 nucleotides in intron 1 is denoted 1 and all other positions are numbered 
in relation to this. Integrations in co-transcriptional orientation with Cd74 are marked by dark grey bars and integrations in antisense orientation are 
marked by light grey bars. The position of primer A-E applied in the RT-PCR analysis in (B) is indicated. (B) RT-PCR analysis on RNA from un-infected 
NMRI spleen with a Cd74-specific exon 5 primer and primer A to E, respectively. (C) Results of RLM-RACE analyses, with RNA from un-infected mice, 
indicating the identified transcriptional initiation region in intron 1 dispersed over app. 100 nucleotides (sequence marked in grey). The position of 
the primer applied for RT-PCR analyses (SR2) in conjunction with a linker-specific forward primer is indicated. (D) Quantitative PCR analyses for detec-
tion of the canonical or the novel alternative transcript, respectively, was performed and copy numbers of the two were estimated from copy-number 
standard-curves derived from amplification on plasmid DNA. The samples included RNA from non-treated NMRI control spleens obtained from two 
animals (dark grey bars) and RNA purified from tumor 01-762 (light grey bar). The relative ratios of canonical and alternative transcripts in the samples 
are depicted in the diagram that represents three independent experiments.Pyrz et al. Molecular Cancer 2010, 9:86
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boring the core sites, the span of which is marked by ver-
tical arrows in Figure 5A, was inserted to drive expression
of luciferase as shown in Figure 5B. In the cellular setting
of HEK293T cells insertion of the promoter fragment
(pGL3F1) resulted in a slight decrease in luciferase activ-
ity as compared to the empty vector (pGL3). Previous
studies of the Cd74 upstream intronic enhancer revealed
lack of activity in SV40 promoter-driven transcription
indicating a unique match between the cognate promoter
and the Cd74  intronic enhancer [18,20]. The pGL3
reporter contains an SV40-enhancer and in order to eval-
uate whether the activity of the novel intronic promoter is
enhanced by one of the Cd74 intronic enhancers, thereby
indicating interdependence between the novel intronic
promoter and Cd74  cognate enhancers, these were
exchanged for the SV40 enhancer (pGL3e1 harboring the
upstream intronic enhancer and pGL3e2 harboring the
downstream enhancer, respectively). Transcriptional acti-
vation experiments clearly showed an increased effi-
ciency of the novel intronic promoter in driving
expression of the reporter gene when put in the context
of the downstream intronic enhancer, as seen by compar-
ing pGL3e2 (without promoter) and pGL2e2F1 (with pro-
moter) in Figure 5B, while the upstream intronic
enhancer only imposed a vague augmentation of pro-
moter activity (compare pGL3e1 with pGL3e1F1 in Fig-
ure 5B). Finally, to mimic the situation in tumors with
proviral integration in intron 1 reporter constructs were
cloned where the SV40 enhancer in pGL3 was exchanged
for the U3 transcriptional enhancer region of the provirus
in sense (pGL3US) and antisense (pGL3UA) orientation,
respectively, in relation to the reporter gene. In this cellu-
lar setting, only the enhancer in antisense orientation
possessed the capability of increasing the efficiency of
reporter gene expression slightly as seen for pGL3UAF1
in Figure 5B.
IFNγ-responsiveness
Inspired by the computational analyses indicating the
p r e s e n c e  o f  a n  I F N  r e g u l a t o r y  f a c t o r  b i n d i n g  s i t e ,  w e
evaluated the IFNγ-responsiveness of the novel promoter
in the murine fibroblastic cell line NIH 3T3, the murine
myeloma cells line MPC11, and the murine osteoblastic
cell line MC3T3, respectively (Figure 6A). The canonical
Cd74 transcript was induced in all cell lines tested in
accordance with previous studies [52,53], and addition-
ally in NIH 3T3 and MPC11 cells IFNγ-treatment of the
cells for 24 hours resulted in induction of the novel alter-
native transcript. However, in several independent exper-
iments we failed to detect IFNγ-mediated induction of
expression of the novel transcript in MC3T3 cells, sug-
gesting differences in promoter activating requirements
between the two Cd74  promoters. The dynamics of
IFNγ-induction of Cd74 transcripts was examined by
qPCR detecting the relative transcript abundance in NIH
3T3 cells after IFNγ-treatment as shown in Figure 6B.
Figure 4 Identification of a novel Cd74 isoform. (A) Alignment of the N-terminal part of the ORFs in the canonical (Cd74Wt) and the novel alter-
native isoform (Cd74Alt), respectively. The two ORFs only differ in the N-terminus and are identical from entry into exon 2, which is illustrated in the 
figure by a grey arrow. The asterisk marks the methionine subject to codon mutation in Cd74Alt_mut in (B) and the arrowhead marks the site of pro-
teolysis. (B) Coupled transcription/translation reaction in vitro with T7-driven expression of Cd74Wt (lane 1), Cd74Alt (lane 2), and Cd74Alt with the 
predicted start codon mutated (lane 3, Cd74Alt_mut) in the presence of 35S-labelled methionine.Pyrz et al. Molecular Cancer 2010, 9:86
http://www.molecular-cancer.com/content/9/1/86
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Figure 5 Identification of a novel intronic Cd74 promoter. (A) The sequence upstream of primer SR2 from the RLM-RACE - position of which is 
indicated in Figure 3C - was applied as query sequence (mm9) to retrieve orthologous sequences from the UCSC genome browser for the indicated 
species assemblies; rat (rn4), human (hg18), marmoset (calJac1), and horse (equCab1). The retrieved sequences were analyzed by Chaos and Dialign 
software [49] and the part depicted displayed the highest similarity within the query sequences upstream of the transcriptional initiation region iden-
tified by RLM-RACE, the start of which is marked by a horizontal arrow above the sequence. The indicated putative binding site core sequences of 
transcription factors expressed in the immune system were identified by the MatInspector software [50]. The vertical arrows mark the start and the 
end, respectively, of the promoter fragment tested functionally in luciferase assays. (B) HEK293T cells were transfected with the firefly luciferase re-
porter pGL3-enhancer (pGL3) or pGL3-derived vectors with the SV40 enhancer in the pGL3-enhancer construct substituted by Cd74 intronic enhanc-
ers (pGL3e1 and pGL3e2) or by the U3 region of the provirus in sense (pGL3US) or antisense (pGL3UA) orientation respectively, and with or without 
the promoter fragment (F1) marked by arrows in (A). Luciferase activity of reporters without an inserted promoter are depicted by light grey bars, 
whereas the activity of equivalent reporters with the F1 promoter region inserted upstream of firefly luciferase are represented by dark grey bars. A 
plasmid encoding Renilla luciferase under the control of a CMV promoter was co-transfected in all experiments. Luciferase activity was measured 48 
hours post transfection, corrected for differences in transfection efficiencies and normalized to the activity of the individual expression vectors with 
the indicated enhancer but without the F1 promoter fragment which was set to 1.Pyrz et al. Molecular Cancer 2010, 9:86
http://www.molecular-cancer.com/content/9/1/86
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The canonical Cd74 transcript was induced app. 20 fold
after 24 hours incubation with 25 ng/ml IFNγ whereas
the amount of intronically initiated transcripts only
reached to a level five times higher than that seen in
untreated control cells. However, when the cells were
treated with IFNγ for 48 hours the levels of fold induction
of the two transcripts were comparable (Figure 6B). The
relative fold induction in transcript expression was con-
firmed in NIH 3T3 cells treated with IFNγ at 50 ng/ml for
24 and 48 hours, respectively (data not shown). This data
collectively underscore the distinctiveness of the regula-
t o r y  m e c h a n i s m s  c o n t r o l l i n g  e x p r e s s i o n  o f  t h e  I F N γ -
inducible canonical and alternative Cd74 transcripts,
respectively.
Discussion
A novel IFNγ-inducible Cd74 isoform expressed from an 
intronic promoter
The identification of a novel intronic promoter in the
Cd74 locus was guided by the proviral insertional pattern
in this locus. However, the promoter was found to be
active in normal un-infected tissues of mice underscoring
its activity in the absence of externally introduced tran-
scriptional regulatory elements such as U3 proviral
enhancer regions, and pointing towards physiological rel-
evance. The transcriptional control elements for the
canonical Cd74 isoform are constituted of a TATA-box
containing promoter with common core promoter motifs
such as CCAAT-box and Sp1 sites, an upstream
enhancer, and two intronic enhancers [18-20]. Notably,
the novel promoter, which is situated downstream of both
intronic enhancers, does not encompass such common
regulatory elements, and transcriptional initiation is dis-
persed over a region of app. 100 bp, which both are char-
acteristics of TATA-less broad-peak promoters [54]. In
this case, the novel promoter is predicted to be under the
control of transcription factors (ETS and MZF1) previ-
ously shown to be important during hematopoietic lin-
eage specification and controlling proliferative capacity of
hematopoietic cells [55,56], and it will be of interest to
verify their involvement in transcriptional regulation of
the novel Cd74 isoform in functional assays.
The activity of the novel intronic promoter is highly
potentiated by the downstream intronic enhancer (Figure
5B). This regulatory unit has been shown to interact with
some of the same factors in vivo as the upstream intronic
enhancer [19], which also to a modest degree influence
the activity of the intronic promoter. The U3 enhancer
region from the provirus augmented the reporter gene
activity only modestly, which was unexpected consider-
ing the fact that U3 enhancer insertion is likely to be the
activating mechanism applied in the tumors with inser-
tions in antisense orientation. However, the activating
potential was evaluated in a cellular setting (HEK293T
cells) other than the one in which it is naturally occurring,
which is believed to be murine B-cells, and in an artificial
system (pGL3-reporter context). We note that only the
reporter with the U3 enhancer in antisense orientation
compared to the reporter gene was active. This is in
accordance with the fact that proviral insertional
enhancer activation in tumors irrespective of target locus
is primarily seen for insertions in inverse transcriptional
orientation to their target gene. In support of a functional
connection between the intronic promoter in intron 1
Figure 6 IFNγ-responsiveness of the novel intronic Cd74 promoter. (A) RT-PCR analysis on RNA from NIH 3T3, MPC11, and MC3T3 cells, detecting 
the canonical transcript initiated in exon 1 (Wt) or the alternative transcript initiated just upstream exon 2 (Alt), respectively, without (-) or with (+) 
IFNγ-stimulation. The RT-PCRs were performed with 1:10 diluted cDNA as template for detection of the canonical Cd74 transcript and with undiluted 
cDNA as template for detection of the transcript encoding the novel isoform. Gapdh-specific RT-PCR is included as control. (B) Quantitative PCR anal-
yses on NIH 3T3 cells treated with 25 ng/ml IFNγ for 24 and 48 hours, respectively, prior to harvest of RNA. The signal of the Cd74 transcript was nor-
malized to the expression level of TATA-box binding protein in individual cDNA preparations and fold induction compared to un-treated NIH 3T3 cells 
was calculated on the basis of three independent experiments.Pyrz et al. Molecular Cancer 2010, 9:86
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and the Cd74 intronic enhancers, none of the insertions
in intron 1 in tumors with proviral integrations in Cd74
disrupt any of these regulatory elements. This collectively
suggests a selection for maintaining functional intronic
enhancers with the capability of acting on both the
upstream and the intronic promoters. In line with this is
that the activity of the 5' intronic enhancer relies on pro-
moter elements other than Sp1-sites and TATA-boxes to
promote transcriptional activation of the canonical Cd74
promoter [18], which intriguingly characterize the novel
promoter.
One of the main transcriptional inducers of Cd74 is
IFNγ and both the upstream and the 5' intronic enhanc-
ers have been shown to be important for IFNγ respon-
siveness [20,52,53], whereas the cell-type restricted
expression of Cd74 is imposed by the promoter [18]. The
MHCII transactivator CIITA is believed to be required
for IFNγ induced transcriptional activation of the canoni-
cal transcript and both intronic enhancers have been
shown to interact with the MHCII transactivator CIITA
in vivo [19]. Interestingly, ETS1 and MZF1 binding sites
are found within the CIITA promoter [57], core
sequences of which are predicted to be conserved in the
novel intronic promoter. This enables a transcriptionally
co-regulated network to act in IFNγ-induction of the
canonical as well as the novel Cd74 isoform through the
common enhancers and cognate promoters. The novel
Cd74 isoform is IFNγ-inducible in agreement with the
presence of an IFN regulatory factor binding site in the
murine promoter sequence, although the functional
impact of this promoter element is not experimentally
verified. In addition to a putative contribution to the
IFNγ-responsiveness from the promoter itself the down-
stream enhancer is envisioned to have great influence on
the inducibility by IFNγ due to its association with CIITA
and its resemblance to the other Cd74  enhancer ele-
ments. The distinctness of the upstream and the intronic
promoters and their different regulation is however man-
ifested through differences in tissues in which the two
transcripts are expressed, levels at which they are
expressed in the respective tissues, differences in which
cell lines the transcripts can be induced upon IFNγ-treat-
ment and the dynamics of transcript prevalence after
IFNγ-stimulation.
The novel intronic promoter drives expression of an N-
terminally truncated alternative Cd74 isoform, the prop-
erties of which currently remain speculative. A detailed
characterization at the protein level faces the challenge of
deducing conclusive arguments in lack of antibodies spe-
cific for one of the isoforms and the close resemblance in
size of the proteins but specific functional assays applying
e.g. FLAG or HIS-tagged proteins are underway to
address some of the questions posed. The novel isoform
is however not expected to induce NF-κB mediated tran-
scriptional activation, as it lacks the N-terminus neces-
sary for this activity [13], nor can it be directly involved in
motility control in a way analogous to the canonical iso-
form as this mechanism is a result of interplay between
the N-terminal cytoplasmic tail of Cd74 and the actin-
based motor protein myosin II [16,58]. However, the for-
mation of the MIF-receptor complex, in which Cd74 con-
stitutes the MIF-binding partner whereas CD44 is the
signaling subunit [10,11], is most likely unaffected by the
absence of the distant cytoplasmic part, as the transmem-
brane region is retained in the novel isoform and
trimerization is independent of the N-terminus [59].
Additionally, as the two isoforms are expressed concomi-
tantly in different tissues formation of mixed trimers can
be envisioned.
Cd74 is a novel common insertion site in MLV-induced B-
lymphomas
L ym p h o m a  i n d u ct i o n  i n  m i c e  b y  M L V s  is  a c h i ev ed  b y
injection of infectious particles within the first 48 hours
after birth to prevent clearance via an immune response
however the state of immunological tolerance seems not
to be absolute [60], and it is plausible that the virus may
initiate/influence immune signaling prone for Cd74 mod-
ulation. Nevertheless, the potential action of immuno-
reactive mechanisms during tumorigenesis mediated by
the viral infection itself does not weaken the genetic argu-
ment brought forward through the identification of Cd74
as a CIS for involvement of the Cd74 locus in the tumori-
genic process.
The Cd74 expression levels, when evaluated on sec-
tions of a tumor and not at the single-cell level, could not
in general be correlated with the status of proviral inser-
tions within the locus. Interestingly, in tumor 01-762
higher amounts of alternative transcripts relative to the
canonical transcript levels were detected by absolute
quantification by qPCR in comparison with spleen from
un-treated mice. Although tumor 01-762 was the only
tumor sample analyzed by this approach and the preva-
lence of the altered ratio among all the tumor samples
therefore remains unknown, it is indicative of transcrip-
tional up-regulation of the novel Cd74 isoform by provi-
ral insertion in this specific tumor. The altered relative
ratio of the two transcript forms was however not accom-
panied by an overall increased Cd74 expression in tumor
01-762, compared to tumors with integrations elsewhere
in the genome, as evaluated by Western blotting (data not
shown). The general lack of correlation between proviral
status and expression levels in end-stage tumors could
reflect tumor heterogeneity, which is supported by
Southern blotting analyses, and/or that consequences of
Cd74 deregulation are manifested at a stage earlier on in
the progression of the tumors. Neoplastic transformation
as a consequence of a transient signal initiating a positivePyrz et al. Molecular Cancer 2010, 9:86
http://www.molecular-cancer.com/content/9/1/86
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feed-back loop has recently been reported [61] and this
mode of action can also be envisioned in the present
model. This does however not exclude possible effects
manifested at a pre-leukemic stage in which case it is a
formal possibility that cells harboring Cd74  proviral
insertions are not selected for during tumor outgrowth in
analogy to that seen for c-myb activation in T-cell lym-
phomas induced by Moloney MLV in BALB/c mice [62].
Conclusively, although the tumors are sub-clonal with
respect to Cd74  integrations, the high frequency with
which this locus is targeted selectively in B-lymphomas
and the obvious non-random distribution of insertion
sites within the locus, with respect to position as well as
orientation, clearly brings Cd74 forward to be a direct
target for deregulation in the B-lymphomagenic process.
Cd74 isoforms; allies in deed
Deregulation of Cd74 expression is associated with dis-
turbed tumor immune surveillance, which in part is
believed to be a result of impaired endogenous tumor
antigen presentation [63,64]. Apart from any disturbance
imposed by the alternative isoform itself, any changes in
canonical Cd74 activity due to its putative association
with the novel isoform could be envisioned to disturb the
fine-tuned balance of immune surveillance mechanisms
holding a tumor at bay. Although no pattern of alternative
transcript expression was evident among different
tumors with insertions in the Cd74  locus (data not
shown), this most likely reflect the heterogenic composi-
tion of these tumors as suggested by other molecular
analyses. Since sequence identity between intronically
initiated transcripts from tumor and un-infected tissues
was established only from exon 4 and upstream it
remains a formal possibility that they differ in their 3'
ends. The novel isoform is envisioned to be found on the
cell surface in elevated amounts compared to the canoni-
cal isoform as it lacks the endosomal localization signals
encoded in exon 1 [65], and its deregulated expression
due to proviral insertions in the individual cells could
increase the pool of available survival receptors prone for
MIF stimulation, thereby directly contributing to the
tumorigenic process, putatively at the initial stages of
malignant transformation. The frequency, position, and
orientation of insertions in intron 1 however, clearly
underscore the involvement of the novel Cd74 isoform
during B-lymphoma development.
Conclusions
By screening app. 2400 MLV-induced tumors for proviral
integration sites we find the Cd74 locus to be a novel
common insertion site in murine B-lymphomas. Inter-
pretation of the proviral insertion pattern in light of dis-
secting genomic structures prompted the identification
of a novel Cd74 isoform expressed from an intronic pro-
moter in a manner different from its canonical counter-
part. Expression of the novel transcript is IFNγ-inducible
and reporter assays suggest the activity of the promoter
to be under influence of the downstream intronic
enhancer.
The essential functions of Cd74 in antigen presentation
and B-cell homeostasis together with its recent applica-
tion as target in immuno-therapy trials, makes a thor-
ough characterization of the protein isoforms of foremost
importance. Furthermore, the status of Cd74 as a vital
component in the pathogenic process per se necessitates a
more profound understanding of the pathogenic contri-
bution of Cd74 in the multi-step process of tumorigenesis
- in which view expression of an alternative Cd74 isoform
only adds to the complexity previously anticipated.
Methods
Origin of lymphomas
In previous studies mice of the inbred NMRI strain were
infected with the non-acutely transforming ecotropic
murine leukemia viruses Akv and SL3-3 and different
mutants hereof, primarily harboring mutations within
the transcriptional control elements. The set-up resulted
in app. 2400 tumors and proviral insertion sites were
determined as previously described [47,66]. Tumor sam-
ples selected for this study were available from our earlier
and unpublished work [41,44,46,48,67,68].
Southern blotting analyses
Clonal rearrangements in Ig and TCR loci were detected
by hybridization of digested genomic DNA extracted
from frozen tissues with appropriate probes. Clonal rear-
rangements in Ig loci were detected by probes derived
from the joining regions of the IgH and Igκ [41], respec-
tively, whereas rearrangements within TCR genes were
evaluated by two separate probes recognizing either join-
ing region 1 or 2 (J1 and J2, respectively) of the TCRβ
chain [69]. The ecotropic virus-specific probe was an
envelope SmaI fragment from Akv [41].
RT-PCR
First-strand cDNA synthesis (Fermentas) was made with
3 μg total RNA and an oligo-dT primer followed by PCR
amplification. For detection of the novel transcript the
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5' TCTGAAGCATCTTAAGAACTCCATGGATG3'.
Detection of canonical transcript was performed with
Exon1forward + Exon4reverse, while detection of the
alternative transcript was performed with
Intron1forward + Exon4reverse unless otherwise stated.
Exon1forward: 5' CTGTGGGAAAAACTAGAGGCTA-
GAG C3', Exon4reverse: 5' ACATGGTCCTGGGTCAT-
GTTGCCGT A3', Intron1forward: 5' TGTCACTA
CACAGAGGAGACACCAAA 3'. Primers for Gapdh
were 5' ACCACAGTCCATGCCATCAC 3' and 5' TCCA-
CCACCCTGTTGCTGTA 3'.
qPCR
For qPCR cDNA was used as template in a SYBR green
qRT-PCR reaction using the Platinum SYBR Green qRT-
PCR Supermix UDG (Invitrogen) following the manufac-
turer's recommendations. Reactions were run in tripli-
cates with cDNA corresponding to 30 ng total RNA. For
absolute quantification standard curves were derived
from amplification on plasmid DNA (expression vectors
for the canonical and novel isoform, respectively). The
primers applied were one in exon 4 of Cd74  (5'
ACATGGTCCTGGGTCATGTTGCCGTA3') in combi-
nation with a primer specific for the canonical transcript
(5' GGGGCTCGAGATGGATGACCAACGCGACC3'),
or with a primer specific for the novel transcript (5'
ATGCTCTTACTCCGTCCCAACAG3'), respectively.
Copy numbers of the two transcripts in the separate
spleen samples and tumor 01-762 were estimated from
copy-number standard-curves derived from amplifica-
tion on plasmid DNA.
Relative quantification was done with the Pfaffl method
[70] normalizing to the expression level of TATA-box
binding protein (TBP) amplified with the primers 5'
AGAGAGCCACGGACAACTG 3' and 5' ACTCTAG-
CATATTTTCTTGCTGCT 3'. Primers in Cd74 were 5'
GTGCAGCCGTGGAGCTCTGTACAC3' (specific for
canonical transcript), 5' GGGGCTCGAGATGC TCT-
TACTCCG TCCCAACAG3' (specific for novel tran-
script) in conjunction with 5' ACGCATCAGCA
AGGGAGTAGCCATCC3' (Cd74 exon 3 reverse primer).
Identification of 5' transcript ends
Identification of the 5' transcript ends was done using the
GeneRacer™ RLM-RACE kit from Invitrogen following
instructions provided by the manufacturer. Briefly, 5 μg
total RNA from spleen was applied, onto which a GeneR-
acer™ RNA oligo was ligated to the 5' end. The ligated
mRNA was reverse transcribed with a gene-specific
primer in exon 5 (5' TCTGGGAAGGTCCCCTT
CAGCTGCGGGTACTCCA3') or it was random-primed
(primer supplied in the RML-5' RACE kit), respectively.
The RNA for gene-specific cDNA-priming was purified
from spleen of an inbred NMRI mouse, whereas RNA for
the randomly primed cDNA-synthesis was purified from
the spleen of a mouse in a backcross breeding program
from B6D2F2 to inbred NMRI mice. To amplify 5' ends,
amplifications were performed with a forward linker
primer and a reverse gene-specific intronic primer (SR2;
5' GCCTCCTCTGGGCTTTGGTGTCTCCTCTGTGTA
GTGACAGGGTAA3') in order to identify transcripts
initiated in intron 1, and the gene-specific exon 5 reverse
primer applied in the cDNA synthesis in order to detect
the canonical transcript initiated in exon 1, followed by
semi-nested PCR with a nested linker primer. Two μl bulk
PCR product was subsequently cloned into the TOPO TA
cloning® system (Invitrogen) and sequenced with the pro-
vided vector primers M13F and M13R, respectively.
In vitro transcription/translation
The single-tube in vitro transcription/translation assay
was performed with the TnT®Quick Coupled Transcrip-
tion/Translation Kit from Promega according to manu-
facturer's recommendations.
In order to obtain the ORFs in a context with a T7
priming site, the canonical p31 Cd74 ORF and the ORF of
the novel isoform (p31-like) were amplified by RT-PCR
from oligo-dT-primed cDNA from NMRI inbred spleen
R N A  a n d  c l o n e d  i n t o  t h e  T O P O  T A  c l o n i n g ®  system
(Invitrogen). The ORFs were cloned including their 8
upstream nucleotides thereby comprising the naturally
occurring Kozak sequence.
In silico analysis
The sequence spanning intron 1 of Cd74 (mm9 assembly
of the murine genome at the UCSC genome browser [71])
was extracted. Orthologous sequence chains from rat,
human, marmoset, horse, and cow, were obtained and
aligned with the murine sequence by global multiple
alignment with the Chaos and Dialign software [49,72].
The largest degree of similarity within this region, except
regions harboring the intronic enhancers, was from 542
nucleotides upstream exon 2 of murine Cd74 and extend-
ing until position 202 upstream of exon 2. Thus, a
sequence of 317 nucleotides, spanning from 542 nucle-
otides upstream of exon 2 and until the start of annealing
of primer SR2 from the RLM-RACE analysis (which
anneals to position 225 T 181 upstream exon 2), was
extracted for further analysis. Orthologous sequences
from rat (rn4 assembly), human (hg18 assembly), marmo-
set (calJac1 assembly), and horse (equCap1 assembly),
were aligned with the murine sequence by Chaos and
Dialign software [49,72]. Transcription factor binding site
sequences were identified by usage of the free academic
MatInspector license from Genomatix [50,73]. Only tran-
scription factor binding motifs with core similarities
higher than 0,85 were considered and furthermore, onlyPyrz et al. Molecular Cancer 2010, 9:86
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transcription factor families expressed in cells of the
immune system were included.
Tissue culture
NIH 3T3 cells were grown in DMEM supplemented with
10% NCS, MC3T3 cells were grown in Mem-a supple-
mented with 10% FCS, and the MPC11 suspension cell
line was cultured in RPMI-1640 supplemented with 10%
FCS. In experiments with IFNγ-treatment, cells were
grown for 24 or 48 hours in the presence or absence of 25
ng/ml IFNγ, respectively, prior to RNA harvest.
Luciferase assay
The Dual-Luciferase Reporter Assay System (Promega)
was performed according to manufacturer's recommen-
dations. The constructs applied were based on
pGL3enhancer (Promega) with or without the promoter
inserted in XhoI/HindIII. The F1 promoter fragment was
amplified from BALB/c genomic DNA with the primers
5' TTATATCTCGAGCCACATGTAAAAACTCTAG-
GCCCCAC 3' and 5' TTATATAAGCTTGAAGAAGGG
TTTTCATCCACTGTGC 3'. The SV40 enhancer was
exchanged for other enhancers in HpaI/BamHI followed
by reintroduction of the luciferase polyA site in the HpaI
site. Enhancers were amplified with 5' TATAAGT-
TAACGCTTCCAAGACTGACCAGGCCTTA 3' and 5'
TATAATGGATCCGTTTTACTTCCTCCTTTGTACT-
TCCTCC 3' (upstream enhancer), 5' TATAATGT-
TAACTCTCCAGCCCTTGGCTTAGGAAATAC 3' and
5' TATAATGGATCCGATAAGTTTGCATCCTGC-
CTACTCCAG 3'(downstream enhancer), 5' TATAAT-
GTTAACAATGAAAGACCCCTTCATAAGGCTT 3'
and 5' TATAATGGATCCCGCCGAGTGTGGGGTTCT-
TACCCTTTTT 3' (U3 in sense), and 5' TATAATGT-
TAACCG CCGAGTGTGGGGTTCTTACCCTTTTT 3'
and 5' TATAATGGATCCAATGAAAGACCCCT-
TCATAAGGCTT 3' (U3 in antisense). Cd74 enhancers
were amplified from genomic BALB/c DNA and the U3
enhancer regions from an Akv-encoding plasmid.
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